Impaired inflammatory responses to multiple Toll-like receptor ligands in alveolar macrophages of streptozotocin-induced diabetic mice

Inflammation Research

Volumn 61, Issue 5, 2012, Pages 417-426

  Yamasawa, Hideaki ^a   Nakayama, Masayuki ^a   Bando, Masashi ^a   Sugiyama, Yukihiko ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Alveolar macrophages; Diabetes; Inflammatory response; Streptozotocin; Toll like receptor

Indexed keywords

FLAGELLIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PEPTIDOGLYCAN; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HYPERGLYCEMIA; INFLAMMATION; INTRACELLULAR SIGNALING; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES;

ANIMALS; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; FLAGELLIN; LIPOPOLYSACCHARIDES; MACROPHAGES, ALVEOLAR; MALE; MICE; MICE, INBRED BALB C; PEPTIDOGLYCAN; RNA, MESSENGER; STREPTOZOCIN; TOLL-LIKE RECEPTORS;

EID: 84863085827     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-011-0426-2     Document Type: Article

References (45)

1. Benfield T, Jensen JS, Nordestgaard BG. Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia. 2007;50:549-54.
2. Kornum JB, Thomsen RW, Riis A, Lervang HH, Schonheyder HC, Sorensen HT. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care. 2008;31:1541-5.
3. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and outcomes of patients with communityacquired pneumonia. A meta-analysis. JAMA. 1996;275:134-41.
4. Kornum JB, Thomsen RW, Riis A, Lervang HH, Schonheyder HC, Sorensen HT. Type 2 diabetes and pneumonia outcomes: a population-based cohort study. Diabetes Care. 2007;30:2251-7.
5. Yende S, van der Poll T, Lee M, Huang DT, Newman AB, Kong L, et al. The influence of pre-existing diabetes mellitus on the host immune response and outcome of pneumonia: analysis of two multicentre cohort studies. Thorax. 2010;65:870-7.
6. Chang FY, Shaio MF. Respiratory burst activity of monocytes from patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1995;29:121-7.
7. Noritake M, Katsura Y, Shinomiya N, Kanatani M, Uwabe Y, Nagata N, et al. Intracellular hydrogen peroxide production by peripheral phagocytes from diabetic patients. Dissociation between polymorphonuclear leucocytes and monocytes. Clin Exp Immunol. 1992;88:269-74.
8. Josefsen K, Nielsen H, Lorentzen S, Damsbo P, Buschard K. Circulating monocytes are activated in newly diagnosed type 1 diabetes mellitus patients. Clin Exp Immunol. 1994;98:489-93.
9. Katz S, Klein B, Elian I, Fishman P, Djaldetti M. Phagocytotic activity of monocytes from diabetic patients. Diabetes Care. 1983;6:479-82.
10. Jansen A, van Hagen M, Drexhage HA. Defective maturation and function of antigen-presenting cells in type 1 diabetes. Lancet. 1995;345:491-2.
11. Ohno Y, Aoki N, Nishimura A. In vitro production of interleukin- 1, interleukin-6, and tumor necrosis factor-alpha in insulindependent diabetes mellitus. J Clin Endocrinol Metab. 1993;77: 1072-7.
12. Kulseng B, Skjak-Braek G, Folling I, Espevik T. TNF production from peripheral blood mononuclear cells in diabetic patients after stimulation with alginate and lipopolysaccharide. Scand J Immunol. 1996;43:335-40.
13. Salvi GE, Collins JG, Yalda B, Arnold RR, Lang NP, Offenbacher S. Monocytic TNF alpha secretion patterns in IDDM patients with periodontal diseases. J Clin Periodontol. 1997;24: 8-16.
14. Lapchak PH, Guilbert LJ, Rabinovitch A. Tumor necrosis factor production is deficient in diabetes-prone BB rats and can be corrected by complete Freund's adjuvant: a possible immunoregulatory role of tumor necrosis factor in the prevention of diabetes. Clin Immunol Immunopathol. 1992;65:129-34.
15. Doxey DL, Nares S, Park B, Trieu C, Cutler CW, Iacopino AM. Diabetes-induced impairment of macrophage cytokine release in a rat model: potential role of serum lipids. Life Sci. 1998;63: 1127-36.
16. Ptak W, Klimek M, Bryniarski K, Ptak M, Majcher P. Macrophage function in alloxan diabetic mice: expression of adhesion molecules, generation of monokines and oxygen and NO radicals. Clin Exp Immunol. 1998;114:13-8.
17. Lambrecht BN. Alveolar macrophage in the driver's seat. Immunity. 2006;24:366-8.
18. Mohsenin V, Latifpour J. Respiratory burst in alveolar macrophages of diabetic rats. J Appl Physiol. 1990;68:2384-90.
19. Sima AA, O'Neill SJ, Naimark D, Yagihashi S, Klass D. Bacterial phagocytosis and intracellular killing by alveolar macrophages in BB rats. Diabetes. 1988;37:544-9.
20. Amano H, Yamamoto H, Senba M, Oishi K, Suzuki S, Fukushima K, et al. Impairment of endotoxin-induced macrophage inflammatory protein 2 gene expression in alveolar macrophages in streptozotocin-induced diabetes in mice. Infect Immun. 2000; 68:2925-9.
21. Sugawara I, Yamada H, Mizuno S. Pulmonary tuberculosis in spontaneously diabetic goto kakizaki rats. Tohoku J Exp Med. 2004;204:135-45.
22. Zykova SN, Jenssen TG, Berdal M, Olsen R, Myklebust R, Seljelid R. Altered cytokine and nitric oxide secretion in vitro by macrophages from diabetic type II-like db/db mice. Diabetes. 2000;49:1451-8.
23. Sherry CL, O'Connor JC, Kramer JM, Freund GG. Augmented lipopolysaccharide-induced TNF-alpha production by peritoneal macrophages in type 2 diabetic mice is dependent on elevated glucose and requires p38 MAPK. J Immunol. 2007;178:663-70.
24. Morran MP, Alexander LA, Slotterbeck BD, McInerney MF. Dysfunctional innate immune responsiveness to Porphyromonas gingivalis lipopolysaccharide in diabetes. Oral Microbiol Immunol. 2009;24:331-9.
25. Mohammad MK, Morran M, Slotterbeck B, Leaman DW, Sun Y, Grafenstein H, et al. Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse. Int Immunol. 2006;18:1101-13.
26. Oshikawa K, Sugiyama Y. Gene expression of Toll-like receptors and associated molecules induced by inflammatory stimuli in the primary alveolar macrophage. Biochem Biophys Res Commun. 2003;305:649-55.
27. Chaudhuri N, Dower SK, Whyte MK, Sabroe I. Toll-like receptors and chronic lung disease. Clin Sci (Lond). 2005;109:125-33.
28. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4:499-511.
29. Kawai T, Takeuchi O, Fujita T, Inoue J, Muhlradt PF, Sato S, et al. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol. 2001;167:5887-94.
30. Raoust E, Balloy V, Garcia-Verdugo I, Touqui L, Ramphal R, Chignard M. Pseudomonas aeruginosa LPS or flagellin are sufficient to activate TLR-dependent signaling in murine alveolar macrophages and airway epithelial cells. PLoS One. 2009;4: e7259.
31. Yamamoto M, Sato S, Mori K, Hoshino K, Takeuchi O, Takeda K, et al. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol. 2002;169: 6668-72.
32. Covert MW, Leung TH, Gaston JE, Baltimore D. Achieving stability of lipopolysaccharide-induced NF-kappaB activation. Science. 2005;309:1854-7.
33. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-76.
34. Iwata H, Soga Y, Meguro M, Yoshizawa S, Okada Y, Iwamoto Y, et al. High glucose up-regulates lipopolysaccharide-stimulated inflammatory cytokine production via c-jun N-terminal kinase in the monocytic cell line THP-1. J Endotoxin Res. 2007;13:227-34.
35. Koziel H, Koziel MJ. Pulmonary complications of diabetes mellitus. Pneumonia. Infect Dis Clin North Am. 1995;9:65-96.
36. Takeuchi O, Hoshino K, Akira S. Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol. 2000;165:5392-6.
37. Drennan MB, Nicolle D, Quesniaux VJ, Jacobs M, Allie N, Mpagi J, et al. Toll-like receptor 2-deficient mice succumb to Mycobacterium tuberculosis infection. Am J Pathol. 2004;164:49-57.
38. Knapp S, WielandCW, van't Veer C, Takeuchi O, Akira S, Florquin S, et al. Toll-like receptor 2 plays a role in the early inflammatory response to murine pneumococcal pneumonia but does not contribute to antibacterial defense. J Immunol. 2004;172:3132-8.
39. Hawn TR, Berrington WR, Smith IA, Uematsu S, Akira S, Aderem A, et al. Altered inflammatory responses in TLR5-deficient mice infected with Legionella pneumophila. J Immunol. 2007;179:6981-7.
40. Fuse ET, Tateda K, Kikuchi Y, Matsumoto T, Gondaira F, Azuma A, et al. Role of Toll-like receptor 2 in recognition of Legionella pneumophila in a murine pneumonia model. J Med Microbiol. 2007;56:305-12.
41. Ogus AC, Yoldas B, Ozdemir T, Uguz A, Olcen S, Keser I, et al. The Arg753GLn polymorphism of the human toll-like receptor 2 gene in tuberculosis disease. Eur Respir J. 2004;23:219-23.
42. Hawn TR, Verbon A, Lettinga KD, Zhao LP, Li SS, Laws RJ, et al. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. J Exp Med. 2003;198: 1563-72.
43. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-95.
44. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes. 2004;53:2079-86.
45. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes-the EURODIAB Prospective Complications Study. Diabetologia. 2005;48:370-8.